<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05007028</url>
  </required_header>
  <id_info>
    <org_study_id>DR180133</org_study_id>
    <secondary_id>2019-002769-37</secondary_id>
    <nct_id>NCT05007028</nct_id>
  </id_info>
  <brief_title>Nitrous Oxide for Late-Life Depression - PROTO-BRAIN</brief_title>
  <acronym>PROTO-BRAIN</acronym>
  <official_title>Nitrous Oxide for Late-Life Depression : a Randomized Controlled Trial With Comparator - PROTO-BRAIN</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Resistant Depression is a common condition in older adults and there is an urgent need for&#xD;
      novel antidepressant in this population. Nitrous Oxide (N2O) has recently shown rapid&#xD;
      antidepressant effect in midlife depression but no study has currently investigated the&#xD;
      efficacy and safety of N2O in Late-Life Depression (LLD), while N2O may prove to be an ideal&#xD;
      treatment for LLD because of glutamatergic antagonism and cerebrovascular effects and also a&#xD;
      relatively good safety profile.&#xD;
&#xD;
      The goal of our study is to compare changes in depressive symptoms after 2 hours, 24 hours, 1&#xD;
      week and 2 week of a 1-hour exposure to EMONO (Equimolar Mixture of Oxygen and Nitrous Oxide)&#xD;
      versus Medical Air.&#xD;
&#xD;
      Secondary Objectives include comparing differences in neuroimaging measures between 3 groups&#xD;
      (responders and non-responders in the EMONO group, and patients in the control group).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Secondary objectives include:&#xD;
&#xD;
        -  To compare changes in Brain Tissue Pulsatility (BTP) as measured with Ultrasound Tissue&#xD;
           Pulsatility Imaging (TPI) between responders in the EMONO group (MADRS change of at&#xD;
           least 50%), non-responders in the EMONO group (MADRS change of no more than 50%) and in&#xD;
           the Air Medical group&#xD;
&#xD;
        -  To compare baseline differences in structural (brain volumes, white matter&#xD;
           hyperintensities) and functional (resting state connectivity in BOLD, Brain Pulsatility&#xD;
           in BOLD, Brain Perfusion in ASL) among the 3 groups&#xD;
&#xD;
        -  To compare changes in depressive and anxiety symptoms between the active and control&#xD;
           group, as assess with Hamilton scale, CGI scale, QIDS-SR, VAS and the STAI scale&#xD;
&#xD;
        -  To compare safety between the active and control group, as assessed with SSI, YMRS,&#xD;
           CADSS, BPRS&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized double blind trial with comparator</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in MADRS</measure>
    <time_frame>Baseline, 2 hours, 24 hours, 1 week, 2 weeks</time_frame>
    <description>montgomery asberg depression scale for symptoms severity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Brain Tissue Pulsatility</measure>
    <time_frame>Baseline and immediately after the intervention</time_frame>
    <description>Indexes of BTP, including BTP amplitudes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI</measure>
    <time_frame>At Baseline</time_frame>
    <description>Structural and Functional MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HDRS 17 items</measure>
    <time_frame>Baseline, 2 hours, 24 hours, 1 week, 2 weeks</time_frame>
    <description>Hamilton Depression Rating Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in QIDS-SR</measure>
    <time_frame>Baseline, 2 hours, 24 hours, 1 week, 2 weeks</time_frame>
    <description>Quick Inventory of Depressive Symptomatology Self Report, Depression severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CGI</measure>
    <time_frame>Baseline, 2 hours, 24 hours, 1 week, 2 weeks</time_frame>
    <description>Clinical Global Impression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in VAS</measure>
    <time_frame>Baseline, 2 hours, 24 hours, 1 week, 2 weeks</time_frame>
    <description>Visual Analog Scale for global well-being self assessement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in STAI</measure>
    <time_frame>Baseline, 2 hours, 24 hours, 1 week, 2 weeks</time_frame>
    <description>State-Trait Anxiety Inventory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SSI</measure>
    <time_frame>Baseline, 2 hours, 24 hours, 1 week, 2 weeks</time_frame>
    <description>Scale for Suicidal Ideation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in YMRS</measure>
    <time_frame>Baseline, 2 hours, 24 hours, 1 week, 2 weeks</time_frame>
    <description>Young Mania Rating Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Clinician Administered Dissociative States Scale</measure>
    <time_frame>Baseline, 2 hours, 24 hours, 1 week, 2 weeks</time_frame>
    <description>CADSS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in BPRS</measure>
    <time_frame>Baseline, 2 hours, 24 hours, 1 week, 2 weeks</time_frame>
    <description>Brief Psychiatric Rating Scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Late-Life Depression</condition>
  <condition>Resistant Depression, Treatment</condition>
  <arm_group>
    <arm_group_label>Nitrous Oxide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active Drug: EMONO (Equimolar Mixture of Oxygen and Nitrous Oxide)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medical air</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control Drug: Medical air : 78% N2 / 22% O2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EMONO</intervention_name>
    <description>Exposure to 1 hour of EMONO via facial mask</description>
    <arm_group_label>Nitrous Oxide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Medical Air</intervention_name>
    <description>Exposure to 1 hour of Medical Air via facial mask</description>
    <arm_group_label>Medical air</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 60-90 years-old&#xD;
&#xD;
          -  Major Depressive Episode according to DSM-5 criteria, confirmed by the MINI - Mini&#xD;
             International Neuropsychiatric Interview&#xD;
&#xD;
          -  MADRS score greater than 20 (Montgomery Asberg Depression Rating Scale)&#xD;
&#xD;
          -  Patient resistant to at least one well-conducted antidepressant treatment, as&#xD;
             documented by the MGH-ATRQ scale&#xD;
&#xD;
          -  Patient who can undergo N2O diffusion via a facial mask&#xD;
&#xD;
          -  Patient who has signed an informed consent&#xD;
&#xD;
          -  Person affiliated with a social security scheme&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Bipolar disorder, schizophrenic disorder, neurodegenerative disease, documented by the&#xD;
             MINI and the MMSE (non-inclusion if MMSE &lt; 24/30), addictive disorder&#xD;
&#xD;
          -  Unstable somatic pathology (including unstable neurological or cardiological diseases&#xD;
             at risk of interfering with N2O diffusion)&#xD;
&#xD;
          -  Presence of active and significant psychotic symptoms, at investigator's discretion&#xD;
&#xD;
          -  Contraindications to EMONO (50%N2O/ 50%O2) : pneumothorax, emphysema, bowel&#xD;
             obstruction, intracranial hypertension, chronic deficiency in vitamin B12 or B9&#xD;
&#xD;
          -  Contraindications to MRI, including claustrophobia&#xD;
&#xD;
          -  Legal incapacity and/or other circumstances unabling the patient to understand the&#xD;
             nature, purpose or consequences of the study&#xD;
&#xD;
          -  A person participating in a drug clinical trial or during a period of exclusion from&#xD;
             any clinical study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Thomas DESMIDT, MD, PhD</last_name>
    <phone>02 34 37 89 52</phone>
    <phone_ext>+33</phone_ext>
    <email>t.desmidt@chu-tours.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital of Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Thomas Desmidt, MD, PhD</last_name>
      <phone>02 34 37 89 52</phone>
      <phone_ext>+33</phone_ext>
      <email>t.desmidt@chu-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Thomas DESMIDT, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 27, 2021</study_first_submitted>
  <study_first_submitted_qc>August 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2021</study_first_posted>
  <last_update_submitted>August 13, 2021</last_update_submitted>
  <last_update_submitted_qc>August 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nitrous Oxide</keyword>
  <keyword>Magnetic Resonance Imaging</keyword>
  <keyword>Ultrasound Tissue Pulsatility Imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

